[
  {
    "ts": null,
    "headline": "BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of a qPCR detection kit as well as an isolation kit for cell-free DNA and exosomal RNA, will be featured in the Asuragen booth (#1429) at the San Antonio Breast Cancer Symposium beginning on December 10t",
    "url": "https://finnhub.io/api/news?id=ea3d331b25b4db68a05ab3fd1669a5b3a5c0d6ac8c39f0e6ddea4235dfb7bd1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733832000,
      "headline": "BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY",
      "id": 131902110,
      "image": "https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of a qPCR detection kit as well as an isolation kit for cell-free DNA and exosomal RNA, will be featured in the Asuragen booth (#1429) at the San Antonio Breast Cancer Symposium beginning on December 10t",
      "url": "https://finnhub.io/api/news?id=ea3d331b25b4db68a05ab3fd1669a5b3a5c0d6ac8c39f0e6ddea4235dfb7bd1d"
    }
  }
]